| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 04/11/2023 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock, par value $0.00001 per share | 04/11/2023 | M(1) | 3,242 | A | $7.77 | 152,521 | D | |||
| Common Stock, par value $0.00001 per share | 04/11/2023 | M(1) | 8,500 | A | $4.68 | 161,021 | D | |||
| Common Stock, par value $0.00001 per share | 04/11/2023 | M(1) | 30,000 | A | $4.88 | 191,021 | D | |||
| Common Stock, par value $0.00001 per share | 04/11/2023 | M(1) | 14,553 | A | $5.8 | 205,574 | D | |||
| Common Stock, par value $0.00001 per share | 04/11/2023 | S(1) | 56,295 | D | $18.0037 | 149,279 | D | |||
| Common Stock, par value $0.00001 per share | 04/12/2023 | M(1) | 37,447 | A | $5.8 | 186,726 | D | |||
| Common Stock, par value $0.00001 per share | 04/12/2023 | M(1) | 4,097 | A | $7.77 | 190,823 | D | |||
| Common Stock, par value $0.00001 per share | 04/12/2023 | S(1) | 41,544 | D | $18 | 149,279 | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (right to buy) | $7.77 | 04/11/2023 | M(1) | 3,242 | 01/03/2021(2) | 01/03/2030 | Common Stock | 3,242 | $0.00 | 16,847(3) | D | ||||
| Stock Option (right to buy | $4.68 | 04/11/2023 | M(1) | 8,500 | 03/31/2021(2) | 03/31/2030 | Common Stock | 8,500 | $0.00 | 8,500 | D | ||||
| Stock Option (right to buy | $4.88 | 04/11/2023 | M(1) | 30,000 | 01/03/2023(2) | 01/03/2032 | Common Stock | 30,000 | $0.00 | 90,000 | D | ||||
| Stock Option (right to buy | $5.8 | 04/11/2023 | M(1) | 14,553 | 01/04/2022(4) | 01/04/2031 | Common Stock | 14,553 | $0.00 | 63,447 | D | ||||
| Stock Option (right to buy | $5.8 | 04/12/2023 | M(1) | 37,447 | 01/04/2022(4) | 01/04/2031 | Common Stock | 37,447 | $0.00 | 26,000 | D | ||||
| Stock Option (right to buy) | $7.77 | 04/12/2023 | M(1) | 4,097 | 01/03/2021(2) | 01/03/2030 | Common Stock | 4,097 | $0.00 | 12,750 | D | ||||
| Explanation of Responses: |
| 1. The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. |
| 2. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 3. The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4. |
| 4. One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| Remarks: |
| /s/ Michael Morneau as Attorney-in-Fact | 04/13/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||